Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» drug pricing
drug pricing
Eli Lilly settles insulin suit for $13.5 million, agrees to keep price cap
Eli Lilly settles insulin suit for $13.5 million, agrees to keep price cap
Washington Post, DC
Eli Lilly
insulin
legal
drug pricing
Flag link:
Johnson & Johnson cites rebates and discounts for drug price increases
Johnson & Johnson cites rebates and discounts for drug price increases
Fierce Pharma
JNJ
drug pricing
drug rebates
drug discounts
Flag link:
Medicaid plans to audit the prices of costliest drugs
Medicaid plans to audit the prices of costliest drugs
ABC News
White House
drug pricing
Medicaid
CMS
Flag link:
House lawmakers, PBM lobby spar over committee hearing
House lawmakers, PBM lobby spar over committee hearing
BioPharma Dive
PBMs
legislation
drug pricing
Flag link:
This panel will decide whose medicine to make affordable. Its choice will be tricky.
This panel will decide whose medicine to make affordable. Its choice will be tricky.
Medical Marketing and Media
drug pricing
Flag link:
After IRA, Minnesota's drug affordability proposal draws PhRMA's ire
After IRA, Minnesota's drug affordability proposal draws PhRMA's ire
Fierce Pharma
Inflation Reduction Act
PhRMA
drug pricing
Minnesota
Flag link:
Pharma, patient advocates clash over Inflation Reduction Act
Pharma, patient advocates clash over Inflation Reduction Act
Clinical Trials Arena
Inflation Reduction Act
drug pricing
patient advocacy groups
innovation
Flag link:
Pfizer CEO Bourla slams Medicare IRA measure as 'negotiation with a gun to your head'
Pfizer CEO Bourla slams Medicare IRA measure as 'negotiation with a gun to your head'
Fierce Pharma
Pfizer
Albert Bourla
drug pricing
Pharma CEOs
Inflation Reduction Act
Flag link:
JAMA: Leqembi could cost Medicare up to $5B per year
JAMA: Leqembi could cost Medicare up to $5B per year
Medical Marketing and Media
Biogen
Eisai
Leqembi
drug pricing
Medicare
Alzheimer's disease
JAMA
Flag link:
Senate health committee seeks to rein in drug prices with four new bills
Senate health committee seeks to rein in drug prices with four new bills
BioSpace
Senate
drug pricing
generics
PBMs
legislation
Flag link:
Gout Disease Control Suffered After FDA-Driven Price Hike: Study
Gout Disease Control Suffered After FDA-Driven Price Hike: Study
BioSpace
FDA
gout
colchicine
drug pricing
Takeda
Colcrys
Flag link:
What you need to know about pharma, PBM execs testifying on insulin prices
What you need to know about pharma, PBM execs testifying on insulin prices
Medical Marketing and Media
PBMs
insulin
diabetes
drug pricing
Sanofi
Novo Nordisk
Eli Lilly
Flag link:
US Senate kicks off fresh round of drug pricing control legislation
US Senate kicks off fresh round of drug pricing control legislation
BioSpace
Senate
legislation
drug pricing
Flag link:
Pharma is clearly not done fighting drug-pricing reforms
Pharma is clearly not done fighting drug-pricing reforms
Medical Marketing and Media
drug pricing
Inflation Reduction Act
PhRMA
Flag link:
Pharma Decries Drug Selection Plans in Medicare Pricing Policy
Pharma Decries Drug Selection Plans in Medicare Pricing Policy
RAPS.org
Medicare
drug pricing
CMS
Inflation Reduction Act
Flag link:
The Inflation Reduction Act: 10 Predictions About Market Access and Drug Channels
The Inflation Reduction Act: 10 Predictions About Market Access and Drug Channels
Drug Channels
Inflation Reduction Act
drug pricing
340B
Medicare Part D
Flag link:
Price cuts lead to feel-good effects for pharma industry
Price cuts lead to feel-good effects for pharma industry
Medical Marketing and Media
pharma industry
drug pricing
insulin
reputation
Flag link:
Bernie Sanders weighs Senate hearing for largest insulin makers
Bernie Sanders weighs Senate hearing for largest insulin makers
Seeking Alpha
Bernie Sanders
diabetes
insulin
drug pricing
Eli Lilly
Sanofi
Novo Nordisk
Senate
Flag link:
Is the pharma industry particularly vulnerable to inflation?
Is the pharma industry particularly vulnerable to inflation?
Pharmaphorum
inflation
drug pricing
Flag link:
Four Trends That Will Pop the $250 Billion Gross-to-Net Bubble—and Transform PBMs, Market Access, and Benefit Design
Four Trends That Will Pop the $250 Billion Gross-to-Net Bubble—and Transform PBMs, Market Access, and Benefit Design
Drug Channels
drug pricing
generics
PBMs
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »